Germany is one of the largest legal cannabis markets on the planet, and serves as the continental cannabis industry leader in Europe. Industry insiders at the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) estimate that the nation’s total legal medical cannabis sales were nearly €1 billion in 2024, and that total roughly doubled in 2025 to €2 billion.

Frankfurt, Germany-based Bloomwell Group, one of Europe’s leading medical cannabis companies, recently conducted a survey of 3,528 medical cannabis patients and determined, among other findings, that the average price being paid for legal medical cannabis flower in Germany was 4.52 euros per gram as of March 2026, down from 5.23 euros per gram in December 2025.

“At the same time, the prescribed quantity of medical cannabis flowers increased by more than 4,500 percent compared to March 2024.” Bloomwell stated in a press release obtained by the International Cannabis Business Conference regarding Q1 2026 medical cannabis prescriptions in Germany.

“In view of more than one million cannabis patients in Germany, 200 tonnes of imported cannabis in 2025, and continuously rising prescription numbers, no one can seriously dispute how many patients have now successfully transitioned from illegal self-medication to legal, medically supervised care. The low prices have made a significant contribution to making medical cannabis affordable for many segments of the population. Digital therapy is therefore the real game changer on the way to legal sources of supply and the most effective political lever for combating the illegal market.” Niklas Kouparanis, Co-Founder and CEO of Bloomwell Group GmbH, stated.

“Statements by politicians who nevertheless speak of a booming black market stand in clear contradiction to the empirical, partly scientifically collected data of the Ekocan Report and undermine the basis for evidence-based political decisions. It is absurd that the very same people making such claims are demanding more restrictions for medical cannabis in the same breath—which would only strengthen that very black market, drive patients back into illegality, and financially harm local German pharmacies in turn.” Mr. Kouparanis added.

Bloomwell’s survey also found that German medical cannabis patients reported significant benefits after consuming medical cannabis, including reducing the use of other prescription medications and avoiding side effects, with highly positive effects on quality of life and work.

“In more than half of the cases (58.9%), patients who had taken other prescription medications before their therapy with medical cannabis were able to discontinue them completely. This rate is particularly high for sleeping pills. 70.1 percent of former opioid patients report experiencing no side effects after completely stopping opioids by using medical cannabis.” Bloomwell stated about its survey findings.

“Patients were able to reduce the use of other prescription medications by taking medical cannabis flowers by an average of 84.5% across all categories. 58.9 % of previously prescribed medications could be discontinued completely. Those who were able to reduce other medications more significantly through the use of medical cannabis reported, on average, significantly fewer or no side effects at all. The intensity of reduction of other prescription medications for patients who no longer experience any side effects is 88.6%. In contrast, those patients who still report side effects or even more side effects were able to reduce other prescription medications by an average of 66% and 44.2%, respectively.” Bloomwell added.

“The main reason for prescribing medical cannabis, besides symptom treatment, is the reduction or avoidance of side effects from other medications. For example, anyone who can completely discontinue opioids by using medical cannabis has a good chance of managing their daily life and work free of side effects. We should therefore not demand restrictions on access to medical cannabis, but rather ensure that doctors are more willing to attempt an individual therapeutic trial with medical cannabis, or at least recommend it and refer patients to colleagues. At the same time, our survey shows that we should finally discuss the great benefits of medical cannabis more openly, instead of exclusively warning about empirically unproven risks and discrediting flowers.” Dr. med. Julian Wichmann, Co-Founder and CEO of Bloomwell GmbH, said.